PV Lifecycle Stage 1 (Development) Challenges for AAV Gene Therapy Products for Rare Diseases

Credits: None available.

Mark Galbraith, Head of Quality Control & Analytical Sciences, Spark Therapeutics, Inc.
Katherine Giacoletti, Principal Scientist, Merck & Co Inc

Credits: None available.

You must be logged in and own this session in order to post comments.